

Assessing the role of serum prolactin levels and coding region somatic mutations of the prolactin gene in Saudi uterine leiomyoma patients

Hanan Abdelhalim ElSokary^{1,2}, Layla Saleh Abdullah³, Amani Ujaimi¹, Nora Naif Sahly⁴, Nisma Mansouri⁴, Babajan Banaganapalli^{1,2}, Noor Ahmad Shaik^{1,2}, Ramu Elango^{1,2*}, Nabeel Bondagji^{2,4*}

¹Department of Genetic Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

²Princess Al-Jawhara Al-Brahim Center of Excellence in Research of Hereditary Disorders, King Abdulaziz University, Jeddah, Saudi Arabia

³Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

⁴Department of Obstetrics and Gynecology, Faculty of Medicine King Abdulaziz University, Jeddah, Saudi Arabia

Submitted: 19 March 2020; **Accepted:** 9 May 2020

Online publication: 7 September 2020

Arch Med Sci 2025; 21 (6): 2741–2750

DOI: <https://doi.org/10.5114/aoms.2020.98658>

Copyright © 2020 Termedia & Banach

Abstract

Introduction: Uterine leiomyomas (UL) are highly prevalent benign smooth muscle tumors, seen in approximately 70% of women. These hormone responsive tumors are also known to secrete prolactin (PRL), a hormone of the anterior pituitary gland. Elevated levels of serum prolactin are a common clinical finding in different gynecological pathologies including UL. However, the underlying causes for this elevation are not yet clear. Therefore, the main objective of this study is to measure the serum PRL in UL patients and also to investigate its molecular connection with coding region somatic mutations of the PRL gene.

Material and methods: The serum PRL levels of UL patients were measured through the ELISA method. The coding region PRL gene mutations in UL and corresponding myometrium tissues were screened through the Sanger sequencing method.

Results: Uterine leiomyoma patients demonstrated significant elevation of the PRL hormone level in serum samples ($p \leq 0.01$). No somatic coding region mutations in the PRL gene were identified. However, four germline variants (c.570G>A, c.205-102T>A, c.312+177T>C and c.269C>T) were detected.

Conclusions: This study is the first one to confirm that serum PRL level elevation among UL patients is not connected to somatic mutations in the PRL gene. However, PRL genetic polymorphisms may indirectly contribute to the disease etiology.

Key words: uterine leiomyomas, PRL gene, prolactin hormone, somatic mutations, polymorphisms.

*Corresponding authors:

Dr. Ramu Elango
Department of Genetic Medicine
Faculty of Medicine
King Abdulaziz University
P.O. Box 80205,
Jeddah-21589
Saudi Arabia
Phone: 00966-12-460 0000,
ext 21074
Fax: 00966-12-460 0000,
ext 20115
E-mail: relango@kau.edu.sa

Prof. Nabeel Bondagji
Department of Obstetrics and Gynecology
Faculty of Medicine
King Abdulaziz University
P.O. Box 80205,
Jeddah-21589
Saudi Arabia
Phone: 00966-12-460000,
ext 18310
Fax: 00966-12-4600000,
ext 20115
E-mail:
nbondagji@kau.edu.sa

Introduction

Uterine leiomyomas (UL) arise from the overgrowth of smooth muscle and connective tissues in the uterus. Although these tumors are benign in nature, they account for different co-morbidities in 70% to 80% of pre-

menopausal women [1, 2]. Leiomyomas may be single or multiple and are classified into four types according to their location, i.e. intramural, subserosal, submucosal and cervical. Clinical symptoms vary between patients, and the most common presentation includes heavy vaginal bleeding, pelvic pain, compression of the ureter and pregnancy complications. Different potential risk factors including obesity, nulliparity, early menarche, age, ethnicity and genetic factors are proposed to contribute in the development of UL [3].

Genetic studies have identified that approximately 40% to 50% of UL tissue samples carry chromosomal abnormalities. The most common abnormality observed in larger fibroids is the chromosomal translocation (t(12;14) (q14-15; q23-24)) [4, 5]. Abnormalities in other chromosomes such as, 2, 7, 8, 12, and 22 were also reported [6]. Additionally, a spectrum of mutations in several genes, including high mobility group AT-hook 2 (HMGA2), mediator complex subunit 12 (MED12), fumarate hydratase (FH), collagen, type IV, alpha 5 and alpha 6 (COL4A5-COL4A6), MTND1 and MTCYB were also identified [7–11]. HMGA2 and MED12 represent the two most common genes with mutations in 80–90% of all UL [3]. The role of epigenetic factors may also be an underlying cause for fibroid development, as evidenced by the tumor specific hypomethylation DNA (DNMT1 and DNMT3A genes) [12]. Comparative genomic hybridization (CGH) analysis has also shown an inverse association between the expression status of miRNA and mRNA genes involved signaling pathways, which are important for cell division and growth. These pathways include WNT, JAK, MAPK, STAT and TGF- β [13, 14]. Also, a genome-wide association study (GWAS) suggested significant association of UL with 3 SNPs (rs7913069, rs12484776 and rs2280543) [15]. A study from KSA further confirms the contribution of rs12484776 to leiomyoma risk among Saudi women [16].

Leiomyomas grow during the reproductive phase and shrink or disappear after menopause, suggesting that they are hormone responsive tumors. Circulating levels of sex steroid hormones such as estrogen, progesterone and prolactin levels are elevated in leiomyoma patients [17, 18]. The specific molecular causes underlying the elevated hormone levels could be attributed to different molecular anomalies including somatic mutations [19], gene polymorphisms [20–22], epigenetics or miRNA related gene expression changes [23]. Over-expression of the prolactin (PRL) gene in leiomyomas is reported in tumor samples [3]. The role of PRL gene somatic mutations is well characterized in a variety of gynecological cancers, such as endometroid adenocar-

cinomas and cervical carcinomas [24]. However, data on the role of somatic mutations in the PRL gene in leiomyomas and their role in influencing circulating prolactin levels is not available. Therefore, in order to explore the role of somatic mutations in the PRL gene, this study screened all the coding regions of the prolactin gene in leiomyomas and matched myometrium tissues. Furthermore, we measured the serum prolactin level in leiomyoma patients and assessed its relationship with PRL gene mutation status and phenotypic features.

Material and methods

Clinical recruitment

This study was approved by the Institutional Ethics Committee on Human Research of King Abdulaziz University Hospital (KAUH), Jeddah. This study recruited fifty Saudi patients clinically diagnosed with leiomyomas through ultrasonography and confirmed through histopathological examination. Additionally, fifty Saudi female control participants, who were confirmed to be free from UL through ultrasonography, were also recruited to assess their serum prolactin levels. Exclusion criteria included pregnant and lactating women, carriers of any gynecological and pituitary gland tumors and those undergoing hormonal therapy. They were mostly of premenopausal age. Clinical data (symptoms and age) and tumor phenotypes (size, number and location) were obtained only for the patients, whereas the basic anthropometric details (height, weight and BMI) and serum prolactin levels were obtained for both patients and control participants. These data were collected through the hospital e-medical records.

Sampling

A total of 100 tissue samples (consisting of both leiomyomas and their corresponding myometrium) were obtained from 50 hysterectomized uteri from the Department of Histopathology at KAUH, Jeddah. Tissues (1–15 mg) were collected in small vials filled with normal saline and stored at -70°C until they were processed for genetic analysis. Tissue samples were collected solely from the patients. For prolactin serum level analysis, 5 ml venous blood samples were withdrawn from all participants (50 UL patients and 50 healthy controls); serum was separated and stored at -20°C , until further use.

Genetic analysis

Genomic DNA isolation

Initially, myometrium and leiomyoma tissues were minced and then DNA extraction was carried

Table I. List of prolactin gene primer sets

Exon		Primer sequence (5'-3')	Annealing temperature [°C]	Product size [bp]
1	F	CCAGGAAAAGGGAAACGAAT	57.6	354
	R	TCCCCTGTTTGAGAACCATT		
2	F	TACACAGTGGAAAGCGTTTG		513
	R	TGGCACTGTCCCTTCTCTCT		
3	F	GGAAGTAGGCGAAAGGGTTA		473
	R	TTGCTGCCACCATCTTACTT		
4	F	GCCTCTAAGCAAAAATCACAA		408
	R	TGAATGACTAGGCTCTTGCTTT		
5	F	TGCCTTTGTCTAAAACCTTGCAT		590
	R	TGTGCAAGGCTAGCTTCTGTT		

out using the QIAamp DNA Tissue extraction kit following the manufacturer's instructions (Qiagen, Alameda, CA, USA). The concentration and purity of DNA were estimated using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific Inc.) at an absorbance of 260 nm. Extracted DNA was tested for its quality using 1% agarose gel electrophoresis and the DNA samples were stored at -20°C until use.

Primer design and polymerase chain reaction

The coding region sequences of the PRL gene were retrieved from Ensembl Genome Browser (http://www.ensembl.org/Homo_sapiens) and the oligonucleotide primer sets flanking exons 1–5 were designed using Primer3plus (<https://primer3plus.com/>) software. Validation of primer sets was done using Primerstat (https://www.bioinformatics.org/sms2/pcr_primer_stats.html) and Blat (<https://genome.ucsc.edu/cgi-bin/hgBlat>) web-servers. The best primer sets were later synthesized at a commercial facility (Table I). Each PCR reaction was carried out in a 25 µl reaction mixture using 1 µl of genomic DNA, 10 pmol of forward and reverse primers, 9.5 µl of distilled water and 12.5 µl of GoTaq Green Master Mix (Promega USA, Cat. #M7122) containing 1X PCR buffer, 1.5 mM magnesium chloride, 0.2 mM dNTPs, and 2 units of Taq DNA polymerase. PCR amplification included 3 steps, an initial denaturation at 95°C for 2 min, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 57.6°C for 30 s and primer extension at 72°C and a final extension step of 72°C for 5 min. After PCR reaction, the amplicons were electrophoresed on 2% agarose gel with size markers, stained with SYBRVR Safe Nucleic Acid Gel stain, (Invitrogen Inc.) and the bands were analyzed using UVitec Gel Documentation system-232 (UVitec, Cambridge, UK).

Sanger sequencing, sequence alignment, and mutation identification

Initially, PCR products of the amplified exons (1–5) were purified using QIA quick PCR Purification Kit following the manufacturer's instructions (Qiagen, Alameda, CA, USA). The purified PCR product was used as a DNA template for cycle sequencing reaction using the ABI 3500 Genetic Analyzer (Life Technologies, USA). Cycle sequencing PCR was carried out using 1 µl of big dye, 2 µl of 5X big dye buffer, 1 µl of either forward or reverse primer, and 1 µl of purified PCR product from 100–300 bp and 5 µl nuclease-free water. Cycle sequencing program conditions were as follows: denaturation at 96°C for 30 s, followed by 25 cycles of denaturation 95°C for 15 s, annealing at 57.6°C for 30 s and extension at 72°C for 2 min, and a final extension step of 72°C for 5 min. All the PCR products were analyzed using the ABI 3500 Genetic Analyzer.

BioEdit v6 software (www.mbio.ncsu.edu/BioEdit/bioedit.html) was used for aligning wild-type and sample sequences in order to identify the variants/mutations. Somatic mutations were sequence changes observed only in leiomyomas and not in their corresponding normal myometrium tissues, whereas germline variants were sequence changes seen in both fibroid and myometrium tissues.

Serum prolactin measurements

The prolactin *in vitro* Enzyme-Linked Immunosorbent Assay (ELISA) kit (Cat No. 4226-19, Cortez Diagnostics, California) was used for the quantitative measurement of prolactin levels of serum samples. Initially, to all the samples, standards and anti-prolactin-horseradish peroxidase enzyme (HRP) were added to a 96-well plate (precoated with anti-prolactin IgG antibodies) where the prolactin and anti-prolactin-HRP bound to the antibody to form a complex. The mixture was incu-

bated at room temperature and then washed to remove any unbound material. Then, a tetramethylbenzidine (TMB) reagent was added, resulting in a blue color as it was catalyzed by HRP. Finally, a stop solution was added to terminate the reaction, causing the color to change from blue to yellow. The intensity of the signal is directly proportional to the amount of prolactin in the sample and the intensity was measured at 450 nm.

In-silico prediction

All the genetic variants were uploaded to the Variant Effect Predictor (VEP) tool, in Human Genome Variation Society (HGVS) format. The output data provided information about the gene, transcripts, variant location, consequence, minor allele frequency (MAF) in population groups and pathogenicity prediction scores generated by different computational web servers [25]. From the output data we selected the prediction results of Scale-Invariant Feature Transform (SIFT) [26], Polymorphism Phenotyping-2 (PolyPhen-2) [27], Combined Annotation Dependent Depletion (CADD) [28], and Functional Analysis through Hidden Markov Models (FATHMM) [29, 30] to define whether the observed variants are damaging, possibly damaging or benign to the function of the prolactin gene.

Statistical analysis

Analysis of serum prolactin levels between patient and control groups was performed using the GraphPad quick calc, v. 6.0 online statistics software (GraphPad Software Inc, USA). The data were expressed as mean \pm standard deviation. The prolactin serum level was compared in patients and controls by the two-tailed *t* test. A statistically significant difference in serum levels was

determined with a 95% confidence interval (95% CI) for odd's ratio to a cut-off *p*-value of < 0.05.

Linkage disequilibrium analysis

The HaploReg webserver explores annotations of the noncoding genome at variants on haplotype blocks [31]. It includes linkage disequilibrium (LD) information from the 1000 Genomes Project, annotations from the Roadmap Epigenomics and the Encyclopedia of DNA Elements (ENCODE) projects, sequence conservation across mammals, effect of SNPs on regulatory motifs and on gene expression from eQTL studies. We used HaploReg (v. 4.1) to identify the tightly linked variants with $r^2 \geq 0.8$ and to examine their effect on gene function.

Results

Clinical analysis

Participants' characteristics

Most of the patients were found to be of menopausal age (54%), whereas control participants were mostly of premenopausal age (59%). Regarding the BMI, 46% of patients were obese (Table II), while more than half (52%) of the control participants were overweight. Patients in this study presented at least one or two symptoms associated with UL; of these the most common were irregular uterine bleeding (46%) and anemia (24%) (Table III).

Leiomyoma characteristics

Histological classification showed that most tumors were the common leiomyoma type (82%) as opposed to cellular leiomyoma (6%) or mitotically active leiomyomas (3%). When investigating the location of leiomyomas, most were found to

Table II. Age, menopausal state and anthropometric characteristics of UL patients

Patient characteristics	Number	%	Mean \pm SD
Age			
Premenopausal (29–40 years)	9	18	36.3 \pm 4.1
Menopausal (41–50 years)	27	54	46.7 \pm 2.3
Postmenopausal (> 51 years)	14	28	54.2 \pm 3.5
Total	50	100	47.2 \pm 7.2
Body mass index			
Normal weight (18.5–25) [kg/m ²]	8	16	21.7 \pm 2.4
Overweight (25–30) [kg/m ²]	19	38	27.6 \pm 1.0
Obese (> 30) [kg/m ²]	23	46	37.6 \pm 5.7
Total	50	100	32.3 \pm 7.0

be intramural (IM) (52%), followed by subserosal (SS) (8%) and submucosal leiomyomas (SM) (4%). The remainder, however, were found to be in a heterogenous form (Table III). Moreover, analysis of the number of occurrence of leiomyomas revealed that multiple leiomyomas (≥ 2 nodes) were greater in number (40/50; 80%) in comparison to single (10/50; 20%) leiomyomas. The average size of leiomyomas was 5.3 ± 4.5 cm, with a range of 0.43–13.3 cm.

Prolactin measurement

Out of 50 UL patients, 44 (88%) were reported to have high prolactin levels, with a mean value of 172.1 ± 139.2 (Pmol/l). The prolactin levels of 50 control participants showed a mean value of 15.18 ± 7.52 (Pmol/l). Statistical analysis showed a highly significant difference ($p < 0.0001$; OR [95% CI] = 156.9200 [117.7971–196.0429]) between groups, indicating a significant elevation of PRL serum level in UL patients.

PRL mutation analysis

The results of direct nucleotide sequencing of PRL gene exons revealed no evidence of somatic mutations in the fibroid tissues, ruling out their role in fibroid development. However, 4 variants – rs6239 (c.570G>A), rs16885980 (c.312+177T>C), rs1205955 (c.205-102T>A) and rs151282935 (c.269C>T) – were found in both fibroid and myometrium tissues (Figure 1). Variant c.570G>A was found in a heterozygous state (G/A) in 5 myometrium and 5 fibroid tissues and homozygous (A/A) in 2 myometrium and 2 fibroid tissues. Similarly, variant c.205-102T>A was found in the heterozygous state (T/A) in 20 myometrium tissues as well as 20 fibroid tissues and, homozygous (A/A) in 7 myometrium tissues and 7 fibroid tissues. Two variants (c.312+177T>C and c.269C>T) though, were only found in the heterozygous state. Variant c.312+177T>C was found in heterozygous state (T/C) in 5 myometrium tissues and 5 fibroid tissues and variant c.269C>T, was also found in heterozygous state (C/T) in 2 myometrium and 2 fibroid tissues respectively (Table IV). Among these 4 variants, 2 (c.269C>T) and c.570G>A were located in the coding region (exon 3 and exon 5) and 2 (c.205-102T>A and c.312+177T>C) in the non-coding region (intron 2 and intron 3). The MAF range for these variants is 0.01 to 0.26 in gnomAD and/or SHGP. Since these variants were found in both the leiomyoma and myometrium tissues, we conclude that they are germline polymorphisms.

Minor allele frequency analysis of PRL variants

The minor allele frequencies (MAF) of the identified variants were retrieved from different da-

Table III. Clinical characteristics of UL patients

Clinical characteristics	Number	%
Co-morbidities		
Irregular uterine bleeding	23	46
Anemia	12	24
Infertility	6	12
Pelvic pain	4	8
Amenorrhea	3	6
No symptoms	2	4
Leiomyoma characteristics		
Type		
Single types		
IM	26	52
SS	4	8
SM	2	4
Heterogenous types		
IM + SS	11	22
IM + SS + SM	4	8
IM + SM	2	4
SS + SM	1	2
Occurrence		
Common	41	82
Cellular	6	12
Mitotically active	3	6

tabases including the 1000 Genomes Project (1KGP), Saudi Human Genome Project (SHGP) and the Great Middle Eastern (GME) Variome Project. Variant. rs6239 was reported across different populations, whereas variant rs151282935 was seen only in the African population as well as being reported in the SHGP and GME (Table IV). Variant rs1205955 was reported in different populations but not the GME. Lastly, variant rs16885980 was seen in different populations and was not reported in the SHGP or GME (Table IV).

In-silico analysis of PRL variants

Table V shows the pathogenicity prediction scores for the four identified PRL variants. The c.269C>T variant was predicted as mostly damaging and possibly damaging by all 4 tools, SIFT, POLYPHEN2, CADD and FATHMM. For the remaining 3 variants (c.570G>A, c.205-102T>A and c.312+177T>C), only the CADD prediction tool predicted them as neutral or tolerated.




Figure 1. ABI sequenced chromatograms showing the detected PRL variants. **A** – c.570 G>A, **B** – c.205-102 T>A, **C** – c.312+177 T>C, **D** – c.269 C>T

Linkage disequilibrium analysis of PRL variants

Linkage disequilibrium analysis of the 4 identified variants revealed that they are in total compliance with Hardy-Weinberg equilibrium. Variant rs6239 (c.570G>A) and rs16885980 (c.312+177T>C) are in strong linkage with each other and with third variant, rs75493272. Variant rs6239 alters the motifs of the CCNT2 gene, whereas variant rs16885980 alters the motifs of different transcription factors (TF) in the PRL gene. The rs1205955 variant is in strong linkage with rs1205960 ($r^2 \geq 0.8$) and similarly alters the motifs of different TFs. The last variant, rs151282935, potentially alters the TF motif of the STAT gene.

Discussion

Uterine leiomyoma is among the most frequent entities encountered in the practice of gynecology by the age of 50 [14]. There are three types of leiomyomas: intramural (most common), subserosal and submucosal leiomyomas [32, 33]. In this study, intramural tumors were the most common type observed, followed by subserosal tumors. Previous studies have reported that approximately 59.8% of patients with intramural fibroids suffer abnormal uterine bleeding [34]. Most of our patients reported to have abnormal uterine bleeding (46%) followed by anemia (24%). Additionally, another common symptom is pelvic pain, reported in more than 30% of UL patients [35]. In the present study however, only 9% of patients experienced pelvic pain. A possible explanation for this may be lack of patient information. Age is a risk factor contributing to the development of UL [36, 37]. Several studies suggest that the prevalence of fibroids increases with age: 60% by the age of 35 and 80% by the age of 50 [34]. In this study, most patients were found to be between 41 and 50 years old (54%), followed by > 51 years (28%) and only 18% of them were less than 40 years old. Similarly, obesity is another risk factor contributing to UL [36]. Previous study reported that most patients were obese (47.1%), followed by patients with normal weight (34.4%) and overweight (18.5%) [38]. Our data are similar in that most patients (46%) were obese; however, overweight (38%) participants outnumbered those of normal weight (16%). Moreover, our control group BMI showed that mostly participants were overweight (52%), followed by obese (26%), and the remaining were normal weight (22%). A possible explanation behind our participants being mostly obese and overweight is that obesity is seen to be increasing among the Saudi population in recent decades [39, 40].

In normal conditions, prolactin is involved in reproduction and homeostasis. In terms of re-

Table IV. PRL genetic variants identified in UL cases

rsID	Chr. position	Nucleotide change	Exon/Intron	MAF					SHGP	GME	Zygoty	Number of UL cases (%)
				1KGP			Caucasians					
				All	African	South-east Asians	South-east Asians	Caucasians				
rs6239	6:22287516	c.570G>A	Exon 5	0.1	0.026	0.105	0.019	0.053	0.035	G/A	5 (10)	
rs1205955	6:22292747	c.205-102T>A	Intron 2	0.3	0.354	0.318	0.273	0.063	-	A/A	2 (4)	
rs16885980	6:22292361	c.312+177T>C	Intron 3	0.1	0.005	0.119	0.021	-	-	T/A	20 (40)	
rs151282935	6:22292581	c.269C>T	Exon 3	0	0.001	-	-	0.001	0.002	A/A	7 (14)	
										T/C	5 (10)	
										C/C	-	
										C/T	2 (4)	
										T/T	-	

MAF – minor allele frequency, rsID – reference SNP cluster identification, 1KGP – 1000 Genomes Project, GME – the Great Middle East Variome Project, SHGP – Saudi Human Genome Program.

Table V. Pathogenicity prediction of variants

Variant	c.DNA	Consequence	SIFT	PolyPhen	CADD	Fathmm
rs6239	c.570G>A	Synonymous variant	–	–	7.663	–
rs16885980	c.312+177T>C	Intron variant	–	–	9.568	–
rs151282935	c.269C>T	Missense variant	Damaging (0.03)	Possibly damaging (0.737)	22.800	Damaging (0.33897)
rs1205955	c.205-102T>A	Intron variant	–	–	0.339	–

production, prolactin exerts multiple effects such as the development of mammary glands and the synthesis and maintenance of milk secretion. Prolactin ensures homeostasis by maintaining a constant internal environment through regulation of the immune system, osmotic balance, and angiogenesis [41]. Prolactin is produced both by the pituitary gland and uterine tissues, including the endometrium and myometrium. Previous studies have shown that PRL may act as a growth factor in human tumorigenesis in breast, prostate, and endometrium [42]. *PRL* is one of the most highly expressed genes among patients with leiomyomas, especially with HMGA2 subtype [3]. The present study has supported the previous study by reporting a statistically significantly higher level of prolactin in serum among UL patients compared to the control group. A study suggested the use of serum prolactin level as a marker to confirm the diagnosis of UL [43]. Leiomyomas have the ability to synthesize prolactin [44]. Additionally, prolactin levels in patients with UL before myomectomy or hysterectomy were significantly elevated when compared to controls [44]. The present study confirms that the serum prolactin level positively correlates with the number and size of leiomyoma.

No somatic mutations were detected in the *PRL* gene, thus ruling out its direct involvement in uterine tumorigenesis. Four genetic variants, i.e. rs6239, rs16885980, rs1205955 and rs151282935, detected in the *PRL* gene are in total compliance with Hardy-Weinberg equilibrium. Although a specific association of these four polymorphisms with UL is not yet reported, it is likely that these variants contribute to the fibroid development through the genes whose expression they control. For example, rs6239 and rs16885980 variants are in strong linkage with each other and with rs75493272 ($r^2 \geq 0.8$). The first variant (rs6239) was found to alter the motifs of the *CCNT2* gene, located on chromosome 2, which plays a role in mitosis [26] and in regulating p53 activity, which is critically impaired in different cancers [29]. The second variant, rs16885980, has been found to disrupt the activity of different transcription factors (TF) in the *PRL* gene – *Foxc1_2*, *Foxd1_*, *Maf_disc2*, *YY1_disc1*, and *YY1_known5* – which further regulates the ex-

pression many driver genes of cancers [45–47]. The third variant, rs1205955, is in strong linkage with variant rs1205960 ($r^2 \geq 0.8$) and has the ability to potentially alter the *PRL* gene transcription motifs such as *AFP1*, *Mef2_known1*, *Mef2_known6*, *Ncx_2*, *Pax-4_2*, *Pou2f2_known8* and *TATA_known*. The fourth variant, rs151282935 (c.269C>T), has however been found to affect the TF motif called *STAT*, which is often overexpressed in various malignancies [48].

Based on the abovementioned indications, it is assumed that these and other germline polymorphisms could potentially influence the *PRL* gene activity through TF motifs, which further regulates different interacting genes. The altered *PRL* gene transcription could be the underlying cause of elevated levels of serum prolactin hormone in UL patients.

A possible explanation for the absence of damaging mutations in the *PRL* gene is that it is a highly conserved gene with a very crucial role in the survival of human beings in the very first years of infancy. Mutations in this gene would be threatening to survival. Hence, a possible hypothesis would be that due to natural selection and survival mechanisms damaging mutations have been eliminated over time.

Moreover, MAF scores of the identified variants further show the rarity of common variants in the *PRL* gene as well. All the variants, excluding variant rs1205955, were found to be either rare or not reported across different populations including the Saudi population. Variant rs1205955, however, was only rare in the Saudi population and not reported in the Middle Eastern database as opposed to other populations. This could be attributed to the high consanguinity rates in the Saudi and Arab populations.

This study sincerely, admits few limitations. This study only generated data from the coding regions of the *PRL* gene and did not cover the non-coding regions such as introns, 3' and 5' regions, which usually affect the transcript expression. Due to inevitable delays in obtaining fresh small tissue biopsies of tumor samples from the histopathology department, we could not measure the prolactin hormone in tissues. Our small sample size may not allow us to generalize our findings to UL. However, our study, being the first one reporting

the lack of PRL gene somatic mutations, could act as a reference for future investigations.

In conclusion, this is the first study from Saudi Arabia to ascertain the elevated PRL serum levels in UL patients. This study has also confirmed the lack of evidence for the role of somatic mutations in the PRL gene in fibroids. This study detected 4 germline variants in the PRL gene whose exact association with fibroid development remains unclear. Hence, we recommend a larger case-control study to verify whether PRL gene germline polymorphisms could act as potential genetic markers for the disease diagnosis, prognosis and/or its treatment.

Acknowledgments

The authors acknowledge KACST for their technical and financial support.

Funding

This project was funded by the King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia under grant No: 1-17-03-009-0011.

Conflict of interest

The authors declare no conflict of interest.

References

- Osinovskaya NS, Malysheva OV, Shved NY, et al. Frequency and spectrum of MED12 exon 2 mutations in multiple versus solitary uterine leiomyomas from Russian patients. *Int J Gynecol Pathol* 2016; 35: 509-15.
- Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. *Environ Health Perspect* 2003; 111: 1037-1054.
- Mehine M. Integrated data analysis reveals Uterine Leiomyoma subtypes with distinct driver pathways and biomarkers. *Proc Natl Acad Sci* 2016; 113: 1315-20.
- Holzmann C, Markowski DN, Koczan D, K pker W, Helmeke BM, Bullerdiek J. Cytogenetically normal uterine leiomyomas without MED12-mutations – a source to identify unknown mechanisms of the development of uterine smooth muscle tumors. *Mol Cytogenet* 2014; 7: 88.
- Mehine M, M kinen N, Heinonen HR, Aaltonen LA, Vahteristo P. Genomics of uterine leiomyomas: insights from high-throughput sequencing. *Fertil Steril* 2014; 102: 621-9.
- El-Gharib MN, Elsobky ES. Cytogenetic aberrations and the development of uterine leiomyomata. *J Obstet Gynaecol Res* 2010; 36: 101-7.
- Baranov VS, Osinovskaya NS, Yarmolinskaya MI. Pathogenomics of uterine fibroids development. *Int J Mol Sci* 2019; 20: 6151.
- Shaik NA, Lone WG, Khan IA, et al. Detection of somatic mutations and germline polymorphisms in mitochondrial DNA of uterine fibroids patients. *Genet Test Mol Biomarkers* 2011; 15: 537-41.
- Ajabnoor G, Mohammed NA, Banaganapalli B, et al. Expanded somatic mutation Spectrum of MED12 gene in uterine leiomyomas of Saudi Arabian Women. *Front Genet* 2018; 9: 552.
- Goracy J, Kaczmarczyk M, Ciechanowicz A, et al. E-selectin gene haplotypes are associated with the risk of myocardial infarction. *Arch Med Sci* 2019; 15: 1223-31.
- Skonieczna K, Jawie n A, Marsza ek A, Grzybowski T. Mitogenome germline mutations and colorectal cancer risk in Polish population. *Arch Med Sci* 2020; 16: 366-73.
- Li S, Chiang T, Richard-Davis G, Barrett JC, Mclachlan JA. DNA hypomethylation and imbalanced expression of DNA methyltransferases (DNMT1, 3A, and 3B) in human uterine leiomyoma. *Gynecol Oncol* 2003; 90: 123-30.
- Karmon AE, Cardozo ER, Rueda BR, Styer AK. MicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention? *Human Reprod Update* 2014; 20: 670-87.
- Islam MS, Protic O, Stortoni P, et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. *Fertil Steril* 2013; 100: 178-93.
- Cha PC, Takahashi A, Hosono N, et al. A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids. *Nat Genet* 2011; 43: 447-50.
- Bondagji NS, Morad FA, Al-Nefaei AA, et al. Replication of GWAS loci revealed the moderate effect of TNRC6B locus on susceptibility of Saudi women to develop uterine leiomyomas. *J Obstet Gynaecol Res* 2017; 43: 330-8.
- Moravek MB, Bulun SE. Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution. *Curr Opin Obstet Gynecol* 2015; 27: 276.
- Ahmed AA, Deif OM, Saad Abd Al-Latif S, ElHussieny Mohamed AM. Serum protein and prolactin in evaluation of uterine fibroids. *Egyptian J Hosp Med* 2019; 76: 3653-8.
- Fumagalli D, Wilson TR, Salgado R, et al. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. *Ann Oncol* 2016; 27: 1860-6.
- Shaik NA, Govindan S, Kodati V, Rao KP, Hasan Q. Polymorphic (CAG)_n repeats in the androgen receptor gene: a risk marker for endometriosis and uterine leiomyomas. *Hematol Oncol Stem Cell Ther* 2009; 2: 289-93.
- Pabalan N, Pineda MR, Jarjanazi H, Christofolini DM, Parente Barbosa C, Bianco B. Association of the +331G/A progesterone receptor gene (PgR) polymorphism with risk of endometrial cancer in Caucasian women: a meta-analysis. *Arch Gynecol Obstet* 2015; 291: 115-22.
- Shaik NA, Lone WG, Khan IA, Rao KP, Kodati VL, Hasan Q. Enhanced transcription of estrogen receptor α and mitochondrial cytochrome b genes in uterine leiomyomas. *Gynecol Endocrinol* 2011; 27: 1094-8.
- George JW, Fan H, Johnson B, et al. Integrated epigenome, exome, and transcriptome analyses reveal molecular subtypes and homeotic transformation in uterine fibroids. *Cell Rep* 2019; 29: 4069-85.e6.
- Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. *Nucleic Acids Res* 2018; 47(D1): D941-D7.
- Shaik NA, Bokhari HA, Masoodi TA, et al. Molecular modelling and dynamics of CA2 missense mutations causative to carbonic anhydrase 2 deficiency syndrome. *J Biomol Struct Dyn* 2020; 38: 4067-80.
- Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. *Nucleic Acids Res* 2012; 40(W1): W452-W7.
- Adzhubei I, Jordan D, Sunyaev S. Predicting functional effect of human missense mutations using PolyPhen-2.

- Curr Protoc Hum Genet 2013; Chapter 7: Unit 7. DOI: 10.1002/0471142905.hg0720s76.
28. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res* 2019; 47(D1): D886-D94.
 29. McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. *Genome Biol* 2016; 17: 122.
 30. Shihab HA, Gough J, Cooper DN, et al. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. *Hum Mutat* 2013; 34: 57-65.
 31. Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. *Nucleic Acids Res* 2016; 44(D1): D877-D81.
 32. Juhasz-Böss I, Jungmann P, Radosa J, et al. Two novel classification systems for uterine fibroids and subsequent uterine reconstruction after myomectomy. *Arch Gynecol Obstet* 2017; 295: 675-80.
 33. Peddada SD, Laughlin SK, Miner K, et al. Growth of uterine leiomyomata among premenopausal black and white women. *Proceed Nat Acad Sci* 2008; 105: 19887-92.
 34. Zimmermann A, Bernuit D, Gerlinger Ch, Schaeffers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. *BMC Women's Health* 2012; 12: 6.
 35. Owen C, Armstrong AY. Clinical management of leiomyoma. *Obstet Gynecol Clin* 2015; 42: 67-85.
 36. Wise LA, Palmer JR, Stewart EA, Rosenberg L. Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study. *Obstet Gynecol* 2005; 105: 563-8.
 37. Othman EE, Al-Hendy A. Molecular genetics and racial disparities of uterine leiomyomas. *Best Pract Res Clin Obstet Gynaecol* 2008; 22: 589-601.
 38. Dandolu V, Singh R, Lidicker J, Harmanli O. BMI and uterine size: is there any relationship? *Int J Gynecol Pathol* 2010; 29: 568-71.
 39. Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, et al. Obesity in Saudi Arabia. *Saudi Med J* 2005; 26: 824-9.
 40. Alnohair S. Obesity in gulf countries. *Int J Health Sci* 2014; 8: 79-83.
 41. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. *Physiol Rev* 2000; 80: 1523-631.
 42. Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. *Trends Endocrinol Metab* 2002; 13: 245-50.
 43. Baban RS. Serum protein and prolactin as diagnostic markers. *Saudi Med J* 2009; 30: 1411-5.
 44. Levy G, Hill MJ, Plowden TC, Catherino WH, Armstrong AY. Biomarkers in uterine leiomyoma. *Fertil Steril* 2013; 99: 1146-52.
 45. Bhagwat AS, Vakoc CR. Targeting transcription factors in cancer. *Trends Cancer* 2015; 1: 53-65.
 46. Capasso M, Lasorsa VA, Cimmino F, et al. Transcription factors involved in tumorigenesis are over-represented in mutated active DNA binding sites in neuroblastoma. *Cancer Res* 2020; 80: 382-93.
 47. Chaudhary S, Islam Z, Mishra V, Rawat S, Md Ashraf G, Kolatkar PR. Sox2: a regulatory factor in tumorigenesis and metastasis. *Curr Protein Peptide Sci* 2019; 20: 495-504.
 48. Quesnelle KM, Boehm AL, Grandis JR. STAT-mediated EGFR signaling in cancer. *J Cell Biochemistry* 2007; 102: 311-9.